IBC Life Sciences Announces Its 2nd International RNAI Event

IBC Life Sciences announced its 2nd international conference on RNAi to be held November 3-4, 2003 at the Hilton Boston Logan Airport in Boston, MA. This two-day event will focus on solutions for the most serious challenges in using RNAi; validating targets and delivery of RNAi in mammalian cells.

(PRWEB) July 27, 2003 -- IBC Life Sciences announced its 2nd international conference on RNAi to be held November 3-4, 2003 at the Hilton Boston Logan Airport in Boston, MA. This two-day event will focus on solutions for the most serious challenges in using RNAi; validating targets and delivery of RNAi in mammalian cells. With the development of RNAi: Breaking Through the Target Validation and In Vivo Therapeutic Bottlenecks, IBC continues to be the leading information provider in therapeutic applications of this unique gene-silencing tool.

The content of this event will feature industry leaders delivering compelling presentations such as:

How Johnson & Johnson is using siRNA in target validation - Dr. Hans Winkler

How DNAX Research Institute of Schering Plough is furthering in vitro validation of targets specific to cancer therapeutics - Dr. Xiaomin Schebye

Successes and Failures of applying antisense delivery to RNAi - Dr. Cy Stein, Albert Einstein College of Medicine

Challenges in delivery to mammalian cells - Dr. David Lewis, Mirus Corporation

Other leading companies sharing valuable insight include Cold Spring Harbor Laboratories, Beckman Research Institute, Alnylam Pharmaceuticals, Harvard Medical School, Stanford University, and Santaris A/S.

This content-rich event will culminate in an interactive panel discussion on "RNAI R&D, Protecting Your Intellectual Property;" to be moderated by Paul Kokulis, LLB, Special Counsel, Morgan Lewis and Bockius. Participants will include Bharat M. Chowrira, Ph.D., J.D., Vice President, Legal Affairs, Licensing & Patent Counsel, Sirna Therapeutics, Inc., Hemi Chopra, Ph.D., MBA, Licensing Officer, Office of Technology Management, University of Massachusetts Medical School, Richard Warburg, Ph.D., J.D., Partner, Foley & Lardner and Tod Woolf, President and CEO, Sequitur, Inc.

Scientific Program Advisors:
John J. Rossi, Ph.D., Chairman, Division of Molecular Biology, Beckman Research Institute of the City of Hope
Ren Xu, Associate Scientist, Amgen, Inc.

ATTENTION CALENDAR EDITORS! For more information on attending RNAi: Breaking Through the Target Validation and In Vivo Therapeutic Bottlenecks, at the Hilton Boston Logan Airport, Boston, MA visit http://www.lifesciencesinfo.com/rnai; call 508-616-5550 or e-mail kpatterson@ibcusa.com.

###